Akebia Therapeutics Announces September 2020 Investor Conference Schedule

Rhea-AI Summary

Akebia Therapeutics (Nasdaq: AKBA) announced its participation in several virtual investor conferences throughout September 2020. Key appearances include John P. Butler (CEO) at Citi's 15th Annual BioPharma Conference on September 9, and at the Morgan Stanley Global Healthcare Conference on September 15. Michel Dahan (COO) and David Spellman (CFO) will join a fireside chat at H.C. Wainwright's Global Investment Conference on September 14. Akebia aims to enhance the lives of those affected by kidney disease, presenting insights into its business strategy during these engagements.

Positive

• Participation in multiple prestigious investor conferences may enhance visibility and investor interest.
• Leadership engagement with investors indicates a commitment to transparency and communication.

Negative

• None.

CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the following virtual investor conferences in September. 

• Citi's 15th Annual BioPharma Conference
  John P. Butler, President and Chief Executive Officer, to participate in virtual one-on-one meetings on Wednesday, September 9.
   
• H.C. Wainwright 22nd Annual Global Investment Conference
  Michel Dahan, Chief Operating Officer, and David Spellman, Chief Financial Officer, to participate in a virtual fireside chat on Monday, September 14, at 10:00 a.m. ET.
   
• Morgan Stanley Virtual 18^th Annual Global Healthcare Conference
  John P. Butler, President and Chief Executive Officer, to participate in a fireside chat on Tuesday, September 15, at 1:15 p.m. ET.
   
• Cantor Virtual Global Healthcare Conference
  John P. Butler, President and Chief Executive Officer, to present on Wednesday, September 16, at 1:20 p.m. ET.

Where applicable, live webcasts of Akebia's presentations will be made available on the Investors section on the Company's website at https://ir.akebia.com.  

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-september-2020-investor-conference-schedule-301125188.html

SOURCE Akebia Therapeutics

FAQ

What conferences will Akebia Therapeutics participate in September 2020?

Akebia will participate in Citi's 15th Annual BioPharma Conference on September 9, H.C. Wainwright's Global Investment Conference on September 14, and Morgan Stanley's Global Healthcare Conference on September 15.

Who is representing Akebia Therapeutics at the September conferences?

John P. Butler (CEO), Michel Dahan (COO), and David Spellman (CFO) will represent Akebia Therapeutics at the September conferences.

What is the purpose of Akebia Therapeutics?

Akebia Therapeutics aims to improve the lives of individuals affected by kidney disease.

Where can I find live webcasts of Akebia's presentations?

Live webcasts of Akebia's presentations will be available on the Investors section of their website.

When is the Cantor Virtual Global Healthcare Conference presentation?

John P. Butler will present at the Cantor Virtual Global Healthcare Conference on September 16 at 1:20 p.m. ET.